Adjuvant treatment of hepatocellular carcinoma after resection

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and surgical resection offers an opportunity for cure in patients fortunate enough to have tumors amenable to resection. Unfortunately, recurrence rates are as high as 70% five years after resection, and recurrent disease proves to be a major obstacle to improving prognosis. Many adjuvant treatments have been utilized after resection in hopes of improving survival and have failed. This review outlines previous adjuvant strategies for patients with resected HCC and discusses potential steps forward to finding a successful adjuvant therapy.

Keywords

Hepatocellular carcinoma / adjuvant therapy / immunotherapy

References

[1] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[2] Llovet JM,Pikarsky E.Hepatocellular carcinoma.Nat Rev Dis Primers2016;2:16018

[3] Du Y,Ding Y.Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.Hepat Mon2012;12:e6031 PMCID:PMC3500771

[4] Greten TF,Li G.Targeted and immune-based therapies for hepatocellular carcinoma.Gastroenterology2019;156:510-24 PMCID:PMC6340758

[5] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[6] Twelves C,Nowacki MP.Capecitabine as adjuvant treatment for stage III colon cancer.N Engl J Med2005;352:2696-704

[7] Bruix J,Mazzaferro V.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol2015;16:1344-54

[8] Zhou J,Fan J.Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.Clin Cancer Res2003;9:6030-7

[9] Xia Y,Li J.Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.Ann Surg Oncol2010;17:3137-44

[10] Ishizuka M,Nemoto T.Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.Asian J Surg2016;39:149-54

[11] Yamamoto T,Liu W.Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2).J Gastroenterol2009;44:228-35

[12] Okuda Y,Yoshida K.Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor.Cancer Sci2003;94:1034-41

[13] Hotta N,Sato K.Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma.Hepatogastroenterology2007;54:2073-7

[14] Ishizuka M,Shimoda M.Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial.Anticancer Res2012;32:5415-20

[15] Yoshida H,Kudo M.Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.Hepatology2011;54:532-40

[16] Kakizaki S,Sato K.Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection.J Gastroenterol Hepatol2007;22:518-22

[17] Mizuta T,Eguchi Y.The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study.Cancer2006;106:867-72

[18] Yoshiji H,Noguchi R.Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.J Hepatol2005;42:687-93

[19] Yoshiji H,Toyohara M.Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.J Hepatol2009;51:315-21

[20] Kojima S,Matsushima-Nishiwaki R,Moriwaki H.Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review).Int J Oncol2004;24:797-805

[21] Muto Y,Ninomiya M.Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.N Engl J Med1996;334:1561-7

[22] Decensi A.Polyprenoic acid in hepatocellular carcinoma.N Engl J Med1996;335:1461; author reply 1461-2

[23] Miao HQ,Navarro E,Zhu Z.Development of heparanase inhibitors for anti-cancer therapy.Curr Med Chem2006;13:2101-11

[24] Liu CJ,Lee PH.Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.World J Gastroenterol2014;20:11384-93 PMCID:PMC4145780

[25] Liu CJ,Lin DY.Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.J Hepatol2009;50:958-68

[26] Zhong JH,Li LQ.Postoperative therapy options for hepatocellular carcinoma.Scand J Gastroenterol2014;49:649-61

[27] Llovet JM,Montaña X.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet2002;359:1734-9

[28] Lo CM,Tso WK.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology2002;35:1164-71

[29] Izumi R,Iyobe T.Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.Hepatology1994;20:295-301

[30] Li JQ,Zhang WZ,Li GH.Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy.J Cancer Res Clin Oncol1995;121:364-6

[31] Zhong C,Li JQ.A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.J Cancer Res Clin Oncol2009;135:1437-45

[32] Peng BG,Li JP.Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus.Am J Surg2009;198:313-8

[33] Li Q,Sun Y.Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases.Dig Surg2006;23:235-40

[34] Ye JZ,Li ZH.Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.World J Gastroenterol2017;23:7415-24 PMCID:PMC5685847

[35] Liu C,Xu J.Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.World J Surg Oncol2016;14:100 PMCID:PMC4818880

[36] Li C,Yan LN.Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria.J Surg Res2017;209:8-16

[37] Lau W,Ho S.Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial.Lancet1999;353:797-801

[38] Lau WY,Leung TW.Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.Ann Surg2008;247:43-8

[39] Chung AY,Machin D.Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.World J Surg2013;37:1356-61

[40] Kohno H,Hayashi T.Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC).Hepatogastroenterology1996;43:1405-9

[41] Kim DY,Kim SU.Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.Oncology2011;81:184-91

[42] Feng M,Feng W,Zheng Y.Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy.Onco Targets Ther2017;10:3001-5 PMCID:PMC5476751

[43] Lai EC,Fan ST,Wong J.Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.Arch Surg1998;133:183-8

[44] Ono T,Nazmy El Assal O,Nagasue N.Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.Cancer2001;91:2378-85

[45] Hirokawa F,Taniguchi K.Is postoperative adjuvant transcatheter arterial infusion therapy effective for patients with hepatocellular carcinoma who underwent hepatectomy?.Ann Surg Oncol2020;27:4143-52

[46] Hamada T,Wada T.Increased survival benefit of adjuvant intra-arterial infusion chemotherapy in HCC patients with portal vein infiltration after hepatectomy.World J Surg2020;44:2770-6

[47] Chen K,Wang H,Xiang G.Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial.PLoS One2013;8:e57397 PMCID:PMC3585398

[48] Akateh C,Conteh L.Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.World J Gastroenterol2019;25:3704-21 PMCID:PMC6676544

[49] Bettinger D,Schultheiss M.Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysis.Liver Cancer2019;8:281-94 PMCID:PMC6738268

[50] Liu L,Yu Q.Narrow-margin hepatectomy resulted in higher recurrence and lower overall survival for R0 resection hepatocellular carcinoma.Front Oncol2020;10:610636 PMCID:PMC7859433

[51] Wang WH,Wu JX.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels.Liver Int2015;35:2603-10

[52] Rong W,Wang L.Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: a 10-year real-world evidence.Chin J Cancer Res2020;32:645-53 PMCID:PMC7666779

[53] Wang L,Yao X.Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion.Oncotarget2017;8:79971-81 PMCID:PMC5668112

[54] Lin H,Liu Y.Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma.ANZ J Surg2018;88:E718-24

[55] Kuzuya T,Kumada T.Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.J Gastroenterol Hepatol2007;22:1929-35

[56] Li N,Shi J.A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection.Ann Surg Oncol2010;17:179-85

[57] Piao CY,Iwasaki Y.Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort.Acta Med Okayama2005;59:217-24

[58] Yoshida H,Goto E.Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.Hepatol Int2008;2:89-94 PMCID:PMC2716870

[59] Kubo S,Takemura S.Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus.Hepatol Res2007;37:94-100

[60] Yang T,Zhai J.High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.Eur J Surg Oncol2012;38:683-91

[61] Yin J,Han Y.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.J Clin Oncol2013;31:3647-55

[62] Llovet JM,Castells L.Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.Hepatology2000;31:54-8

[63] Chen LT,Li LA.Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular CarcinomaTaiwan Cooperative Oncology GroupNational Health Research InstitutesZhunanTaiwanLong-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.Ann Surg2012;255:8-17

[64] Lo CM,Chan SC.A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.Ann Surg2007;245:831-42 PMCID:PMC1876947

[65] Lin SM,Hsu CW.Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.Cancer2004;100:376-82

[66] Mazzaferro V,Schiavo M.HCC Italian Task ForcePrevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.Hepatology2006;44:1543-54

[67] Kubo S,Hirohashi K,Shuto T.Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.Br J Surg2002;89:418-22

[68] Nishiguchi S,Kubo S.Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma.Intervirology2005;48:71-5

[69] Shiratori Y,Teratani T.Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.Ann Intern Med2003;138:299-306

[70] Sun HC,Wang L.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.J Cancer Res Clin Oncol2006;132:458-65

[71] Ikeda K,Saitoh S.Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.Hepatology2000;32:228-32

[72] Lee D,Kim JA.Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.Cancer2013;119:2239-46

[73] Hsu YC,Wu MS,Wu CY.Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.Hepatology2013;58:150-7

[74] Rosenberg SA.Adoptive cell transfer as personalized immunotherapy for human cancer.Science2015;348:62-8 PMCID:PMC6295668

[75] Rosenberg SA,Sherry RM.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res2011;17:4550-7 PMCID:PMC3131487

[76] Tran E,Gros A.Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.Science2014;344:641-5 PMCID:PMC6686185

[77] Wang Y,Wu M,Cong W.Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.Chin Med J (Engl)1997;110:114-7

[78] Takayama T,Makuuchi M.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.Lancet2000;356:802-7

[79] Shimizu K,Aruga A.Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.Hum Vaccin Immunother2014;10:970-6 PMCID:PMC4896569

[80] Kawata A,Hosokawa M.Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone.Am J Clin Oncol1995;18:257-62

[81] Xie L,Jin Y,Li H.Effects of hepatic artery chemotherapeutic embolization combined with perfusing LAK cells into hepatic artery after radical operation of liver cancer.Zhonghua Gan Zang Bing Za Zhi2000;8:142-3. (in Chinese)

[82] Lee JH,Lee Y.Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study.Oncoimmunology2017;6:e1328335 PMCID:PMC5543846

[83] Sawada Y,Ofuji K.Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.Oncoimmunology2016;5:e1129483 PMCID:PMC4910752

[84] Taniguchi M,Yoshikawa T.Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.Cancer Sci2020;111:2747-59 PMCID:PMC7419030

[85] Kuang M,Lu MD.Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.Clin Cancer Res2004;10:1574-9

[86] Schmidt-Wolf IG,Mehta BA.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.Exp Hematol1993;21:1673-9

[87] Lee JH,Lim YS.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.Gastroenterology2015;148:1383-91.e6

[88] Pan K,Wang W.The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.Ann Surg Oncol2013;20:4305-11

[89] Chen J,Lin X.Adjuvant cytokine-induced killer cell therapy improves disease-free and overall survival in solitary and nonmicrovascular invasive hepatocellular carcinoma after curative resection.Medicine2016;95:e2665 PMCID:PMC4748913

[90] Hui D,Jian W,Da-Lu K.A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.Dig Liver Dis2009;41:36-41

[91] El-khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[92] Huppert LA,Kelley RK.Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma.Clin Liver Dis (Hoboken)2020;15:53-8 PMCID:PMC7098670

[93] Brown ZJ,Heinrich B.Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy.Hepatology2019;70:1437-42

[94] Portolani N,Ghidoni S.Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.Ann Surg2006;243:229-35 PMCID:PMC1448919

[95] Cheng Z,Qu S.Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection.HPB (Oxford)2015;17:422-7 PMCID:PMC4402053

[96] Imamura H,Tanaka E.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003;38:200-7

[97] Poon RT,Ng IO,Liu C.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma.Cancer2000;89:500-7

[98] Borel F,Jansen PL.Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma.J Hepatol2012;56:1371-83

[99] Budhu A,Forgues M.Identification of metastasis-related microRNAs in hepatocellular carcinoma.Hepatology2008;47:897-907

[100] Ji J,Budhu A.Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.Hepatology2015;62:481-95 PMCID:PMC4515211

[101] Zhang DY,Guo J.A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.Gut2016;65:1754-64 PMCID:PMC4848165

[102] Ng KK,Pang HH.A simplified prediction model for early intrahepatic recurrence after hepatectomy for patients with unilobar hepatocellular carcinoma without macroscopic vascular invasion: an implication for adjuvant therapy and postoperative surveillance.Surg Oncol2019;30:6-12

[103] Pan QZ,Zhou YQ.CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.Cancer Immunol Immunother2020;69:825-34

[104] Ji J,Budhu A.MicroRNA expression, survival, and response to interferon in liver cancer.N Engl J Med2009;361:1437-47 PMCID:PMC2786938

[105] Tayyab GUN,Nasir B,Abou-Samra AB.Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.BMC Gastroenterol2020;20:93 PMCID:PMC7137260

[106] Hassany M,Maged A.Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.Eur J Gastroenterol Hepatol2018;30:876-81

[107] Zhang Q,Ku XM.Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma.Eur J Cancer Prev2007;16:196-202

[108] Chen ZN,Xu J.Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.Int J Radiat Oncol Biol Phys2006;65:435-44

[109] Li J,Yang Y.Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial.Lancet Gastroenterol Hepatol2020;5:548-60

[110] Ishikawa T,Sugitani S.Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma.J Gastroenterol Hepatol2001;16:452-9

[111] Fukutomi Y,Muto Y,Okuno M.Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5).Jpn J Cancer Res1990;81:1281-5 PMCID:PMC5918005

[112] Okamura J,Fujiyama T.An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies.World J Surg1982;6:352-7

[113] Tsai TJ,Lui WY.Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma.Surgery2000;127:603-8

[114] Xu L,Chen MS.Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.J Hepatol2015;63:122-30

[115] Qi YP,Liang ZY.Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion.Am J Surg2019;217:739-44

[116] Park JY,Yoon YJ.Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.Cancer2007;110:129-37

[117] Uchida M,Kubota H.Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma.World J Surg1996;20:326-31

[118] Lin CC,Chen WT.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment.Liver Cancer2015;4:228-40 PMCID:PMC4698647

[119] Chan AC,Yuen WK.Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma.Arch Surg2011;146:675-81

[120] Chuma M,Kamiyama T.The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.J Gastroenterol2009;44:991-9

[121] Huang G,Shen F.Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.Ann Surg Oncol2013;20:1482-90

[122] Wu CY,Ho HJ.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection.JAMA2012;308:1906-14

[123] Huang G,Wang ZG.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.Ann Surg2015;261:56-66

[124] Yao FY,Freise C,Bass NM.Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.Hepatology2001;34:411-6

[125] Huang G,Lau WY.Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial.Ann Surg2018;268:943-54

[126] Ghany MG,Thomas DL.American Association for the Study of Liver DiseasesDiagnosis, management, and treatment of hepatitis C: an update.Hepatology2009;49:1335-74 PMCID:PMC7477893

[127] Peng BG,Kuang M.Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma.Jpn J Cancer Res2002;93:363-8 PMCID:PMC5927015

[128] Palmer DH,Mirza N.A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.Hepatology2009;49:124-32